Advertisement
The Leading Source for Pharmaceutical & Biopharmaceutical Manufacturing News
Subscribe to Pharmaceutical Processing

The Lead

Bayer Selects Cardinal Health as U.S. Based Contract Manufacturer for Xofigo Injection

December 18, 2014 | News | Comments

Bayer HealthCare and Cardinal Health have signed a 15-year agreement for the contract manufacturing of Xofigo.  As part of the agreement, Cardinal Health will build a state-of-the art, 64,000 square foot facility in Indianapolis, which will be dedicated exclusively to the manufacturing of Xofigo.

TOPICS:
View Sample

FREE Daily Email Newsletter

Low Migration Labels for Plastic Containers

December 18, 2014 2:23 pm | Product Releases | Comments

Low migration labels are ideal for use in plastic containers, which are increasingly being used in lieu of glass in primary pharmaceutical packaging. Utilizing qualified adhesive systems, materials and inks, specialty labels can be customized to suit a wide range of plastic container packaging applications.

Auxiliary Loaded Regulator

December 18, 2014 1:43 pm | Product Releases | Comments

The ALR-1 features a CA1 back pressure regulator mounted onto it like the previously introduced ULR-1 and PTR-1 valves. Instead of the inlet pressure feeding into the cover dome, an auxiliary air supply, such as air from a compressor, will feed the cover dome.

Biothera Joins Cancer Research UK Combinations Alliance

December 18, 2014 11:36 am | News | Comments

Biothera has joined AstraZeneca, Astex Pharmaceuticals, Eli Lilly and Company, MedImmune and Verastem as the latest pharmaceutical partner in Cancer Research UK's Combinations Alliance.           

TOPICS:
Advertisement

Tetraphase Soars After Releasing Clinical Trial Results

December 18, 2014 11:08 am | by The Associated Press | News | Comments

The Watertown, Massachusetts, company said eravacycline proved to be not inferior to a competing drug, ertapenem, and patients taking it had no serious, drug-related side effects, according to early results from the study.     

TOPICS:

GSK Reports Positive Outcome of Phase III Study of Shingles Vaccine Containing Agenus Adjuvant

December 18, 2014 10:58 am | News | Comments

Agenus and its partner GlaxoSmithKline have reported that the ZOE-50 Phase III study met its primary endpoint. Analysis of the primary endpoint showed that HZ/su reduced the risk of shingles by 97.2% in adults aged 50 years and older compared to placebo.

TOPICS:

Pfizer Reports Top-Line Results from a Phase III Pain Study

December 18, 2014 10:08 am | News | Comments

Pfizer has announced top-line results from a double-blind Phase III study evaluating pregabalin controlled-release (CR) formulation in adult patients with postherapeutic neuralgia (pain after shingles or PHN).        

TOPICS:

Colorado Funds Medical Marijuana Research

December 18, 2014 9:44 am | by KRISTEN WYATT, Associated Press | News | Comments

The grants awarded by the Colorado Board of Health will go to studies on whether marijuana helps treat epilepsy, brain tumors, Parkinson's disease and post-traumatic stress disorder. Some of the studies still need federal approval.   

TOPICS:

Experts: It Was A Busy, Black-Eye Year for Disease Control

December 18, 2014 9:32 am | by MIKE STOBBE, AP Medical Writer | News | Comments

Health officials are celebrating some important victories in 2014, and Time magazine even named Ebola fighters the persons of the year. Nevertheless, this was a black-eye year for public health.          

TOPICS:
Advertisement

European Commission Approves Lynparza™ for Advanced BRCA-Mutated Ovarian cancer

December 18, 2014 9:04 am | News | Comments

AstraZeneca today announced that the European Commission has granted Marketing Authorization for Lynparza™ capsules as the first therapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cance.

TOPICS:

Supplement Maker Lied About Ingredients

December 18, 2014 8:47 am | News | Comments

Federal prosecutors say the owner and president of a dietary supplement company has admitted his role in the sale of diluted and adulterated dietary ingredients and supplements sold by his company.               

TOPICS:

Painkillers Lawsuit Against NFL Dismissed

December 18, 2014 8:40 am | News | Comments

A federal judge dismissed a lawsuit by 1,300 former players against the NFL, writing that the collective bargaining agreement between the league and the union was the appropriate forum to resolve claims that teams damaged the players' by routinely dispensing painkillers.

TOPICS:

More Setbacks for Efforts to Cure HIV Infections

December 18, 2014 8:17 am | by MARILYNN MARCHIONE, AP Chief Medical Writer | News | Comments

Researchers are reporting another disappointment for efforts to cure infection with the AIDS virus. Six patients given blood-cell transplants similar to one that cured a man known as "the Berlin patient" have failed, and all six patients died. 

TOPICS:

Merck Acquires OncoEthix for $110M

December 18, 2014 8:05 am | News | Comments

Merck has acquired, through a subsidiary, OncoEthix, a Swiss-based privately held biotechnology company specializing in oncology drug development. Through the acquisition, Merck has gained an investigational, novel oral BET inhibitor, OTX015, which is currently in Phase 1b studies for the treatment of hematological malignancies and advanced solid tumors.

TOPICS:

United Therapeutics Announces Executive Promotions and CEO Compensation Change

December 17, 2014 3:11 pm | News | Comments

United Therapeutics Corporation has announced two senior executive promotions as well as changes to Martine Rothblatt, Ph.D's compensation program.                 

TOPICS:

Study: Removing Clot Helps Limit Stroke Disability

December 17, 2014 2:54 pm | by MARILYNN MARCHIONE, AP Chief Medical Writer | News | Comments

Researchers in the Netherlands found that mechanically removing a clot in addition to using a clot-busting medicine lowered the risk that a stroke sufferer would end up severely disabled.           

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading